maritide amgen - Search News

News

Amgen, weight loss

Amgen Shares Fall on Weight-Loss Drug Tummy Troubles

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that lots of patients had stopped taking Amgen’s experimental weight loss shot after experiencing gastrointestinal distress.

AOL · 13h

Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.

Reuters on MSN · 12h

Amgen experimental weight-loss drug needs lower dose to limit side effects

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting on Monday that pushed the company's shares down nearly 6%.

14h

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

STAT16h

Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Results From Amgen's Phase 2 Obesity Study Of Monthly Maritide Presented At The American Diabetes Association 85th Scientific Sessions

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

Devdiscourse13h

Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Healio13h

Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

18d

Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN stock is a Buy.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results